BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hashimoto T, Yosipovitch G. Itching as a systemic disease. Journal of Allergy and Clinical Immunology 2019;144:375-80. [DOI: 10.1016/j.jaci.2019.04.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Fourzali KM, Yosipovitch G. Management of Itch in the Elderly: A Review. Dermatol Ther (Heidelb) 2019;9:639-53. [PMID: 31549284 DOI: 10.1007/s13555-019-00326-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
2 Lipman ZM, Paramasivam V, Yosipovitch G, Germain MJ. Clinical management of chronic kidney disease-associated pruritus: current treatment options and future approaches. Clin Kidney J 2021;14:i16-22. [PMID: 34987779 DOI: 10.1093/ckj/sfab167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Hashimoto T, Yosipovitch G. Itchy body: Topographical difference of itch and scratching and C Nerve fibres. Exp Dermatol 2019;28:1385-9. [DOI: 10.1111/exd.14054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 [DOI: 10.1101/2020.10.26.354654] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Ingrasci G, Lipman ZM, Hawash AA, Girolomoni G, Yosipovitch G. The pruritogenic role of the type 2 immune response in diseases associated with chronic itch. Exp Dermatol 2021;30:1208-17. [PMID: 34033148 DOI: 10.1111/exd.14401] [Reference Citation Analysis]
6 Kiguchi N, Ding H, Park SH, Mabry KM, Kishioka S, Shiozawa Y, Alfonso Romero-Sandoval E, Peters CM, Ko MC. Functional roles of neuromedin B and gastrin-releasing peptide in regulating itch and pain in the spinal cord of non-human primates. Biochem Pharmacol 2022;198:114972. [PMID: 35189108 DOI: 10.1016/j.bcp.2022.114972] [Reference Citation Analysis]
7 Fourzali K, Yosipovitch G. Safety considerations when using drugs to treat pruritus. Expert Opin Drug Saf 2020;19:467-77. [PMID: 32064980 DOI: 10.1080/14740338.2020.1728252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wilson BN, Balogh EA, Feldman SR. Medications in dermatology are safer and more efficient than they used to be. Expert Opin Drug Saf 2020;19:359-60. [PMID: 32065544 DOI: 10.1080/14740338.2020.1731171] [Reference Citation Analysis]
9 Burgmann J, Biester T, Grothaus J, Kordonouri O, Ott H. Pediatric diabetes and skin disease (PeDiSkin): A cross-sectional study in 369 children, adolescents and young adults with type 1 diabetes. Pediatr Diabetes 2020;21:1556-65. [PMID: 32985057 DOI: 10.1111/pedi.13130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Fourzali K, Golpanian RS, Yosipovitch G. Emerging drugs for the treatment of chronic pruritic diseases. Expert Opin Emerg Drugs 2020;25:273-84. [PMID: 32715798 DOI: 10.1080/14728214.2020.1801632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Sugita K, Soyka MB, Wawrzyniak P, Rinaldi AO, Mitamura Y, Akdis M, Akdis CA. Outside-in hypothesis revisited: The role of microbial, epithelial, and immune interactions. Ann Allergy Asthma Immunol 2020;125:517-27. [PMID: 32454094 DOI: 10.1016/j.anai.2020.05.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Misery L, Belloni Fortina A, El Hachem M, Chernyshov P, Kobyletzki L, Heratizadeh A, Marcoux D, Aoki V, Zaniboni M, Stalder J, Eichenfield L. A position paper on the management of itch and pain in atopic dermatitis from the International Society of Atopic Dermatitis (ISAD)/Oriented Patient‐Education Network in Dermatology (OPENED) task force. J Eur Acad Dermatol Venereol 2021;35:787-96. [DOI: 10.1111/jdv.16916] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
13 Inan S, Cowan A. Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans. Handb Exp Pharmacol 2020. [PMID: 33296031 DOI: 10.1007/164_2020_420] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Wala K, Szepietowski JC. Difelikefalin in the Treatment of Chronic Kidney Disease-Associated Pruritus: A Systematic Review. Pharmaceuticals 2022;15:934. [DOI: 10.3390/ph15080934] [Reference Citation Analysis]
15 Nattkemper LA, Fourzali K, Yosipovitch G. Cutaneous Gene Expression in Primates with Itch. J Invest Dermatol 2021;141:1586-8. [PMID: 33345969 DOI: 10.1016/j.jid.2020.11.017] [Reference Citation Analysis]
16 Vander Does A, Levy C, Yosipovitch G. Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments. Am J Clin Dermatol 2022. [PMID: 35900649 DOI: 10.1007/s40257-022-00710-2] [Reference Citation Analysis]
17 Salao K, Sawanyawisuth K, Winaikosol K, Choonhakarn C, Chaowattanapanit S. Interleukin-31 and Chronic Pruritus of Unknown Origin. Biomark Insights 2020;15:1177271920940712. [PMID: 32684747 DOI: 10.1177/1177271920940712] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
18 Kim HS, Yosipovitch G. The Skin Microbiota and Itch: Is There a Link? J Clin Med 2020;9:E1190. [PMID: 32331207 DOI: 10.3390/jcm9041190] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
19 Hashimoto T, Mishra SK, Olivry T, Yosipovitch G. Periostin, an Emerging Player in Itch Sensation. J Invest Dermatol 2021:S0022-202X(21)01116-7. [PMID: 34023128 DOI: 10.1016/j.jid.2021.03.009] [Reference Citation Analysis]
20 Lipman ZM, Ingrasci G, Yosipovitch G. Approach to the Patient with Chronic Pruritus. Med Clin North Am 2021;105:699-721. [PMID: 34059246 DOI: 10.1016/j.mcna.2021.04.007] [Reference Citation Analysis]
21 Gurnani P, Miloh T, Chandar J, Landau DA, Hajjar F, Yosipovitch G. Systemic causes of non-dermatologic chronic pruritus in the pediatric population and their management: An unexplored area. Pediatr Dermatol 2021;38:1051-60. [PMID: 34515372 DOI: 10.1111/pde.14596] [Reference Citation Analysis]
22 Kremer AE. What are new treatment concepts in systemic itch? Exp Dermatol 2019;28:1485-92. [DOI: 10.1111/exd.14024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
23 Trivella J, Levy C. Safety considerations for the management of cholestatic itch. Expert Opin Drug Saf 2021;20:915-24. [PMID: 33836644 DOI: 10.1080/14740338.2021.1915984] [Reference Citation Analysis]